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Do We Need to Measure LV Mass and Geometry in Everyone?*Sheldon E. Litwin, MDSEE PAGE 1007M orphometry refers to the quantitative anal-ysis of form, including parameters such assize and shape. The study of morphomet-
rics enables investigators to test hypotheses about
the factors that affect shape. Cardiovascular physiolo-
gists have had a long-standing interest in size, shape,
and structure of the heart. Four morphologic cate-
gories have been deﬁned based on left ventricular
(LV) mass and relative wall thickness (normal,
concentric remodeling, concentric hypertrophy, and
eccentric hypertrophy). All of the abnormal patterns
have prognostic relevance (1). Gaasch and Zile (2)
proposed a more granular classiﬁcation system that
adds 3 additional patterns (mixed hypertrophy, phys-
iologic hypertrophy, and eccentric remodeling).
Traditional thinking holds that chronic pressure and
volume overload lead to distinct LV geometric pat-
terns. In reality, many patients have some combina-
tion of both, and the severity of each hemodynamic
abnormality may vary over time. Obesity, present in at
least 30% of adults, tends to produce a concentric
pattern (3,4). However, the obesity-related changes in
cardiac structure are only partially related to blood
pressure (3). Interestingly, the degree of nocturnal
hypoxemia in patients with sleep-disordered breath-
ing is a predictor of LV hypertrophy, suggesting a role
for oxidative stress (3). Hemodynamic factors that
affect LV mass are interwoven with important modi-
ﬁers such as sex, race, age, genetic variations (geno-
mics), protein expression and function (proteomics),
metabolic proﬁles (metabolomics), exercise habits,
pharmacological treatments, and others (5). Perhaps
the study of cardiac structure is a large enough
endeavor to deserve its own name, for example, “car-
diac morphomics.”*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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increased incidence of cardiac events as well as car-
diac and total mortality (1). Arguments favoring a
direct pathological role include the fact that LV
hypertrophy can adversely affect myocardial perfu-
sion, stiffness, and repolarization. In addition,
regression of LV mass achieved by treatment of
hypertension (6), aortic stenosis (7), and obesity (8)
have been associated with improved outcomes (6,7).In this issue of iJACC, Hoang et al. (9) report
relationships between indexed LV mass, determined
by M-mode echocardiography, and outcomes (coro-
nary heart disease, stroke, heart failure, cardiovas-
cular death, and total mortality) in 3,724 older
adults participating in the Cardiovascular Health
Study. Over a mean follow-up period of 14.2 years,
58% of the subjects experienced a cardiovascular
event, and 26% died of cardiovascular causes. Pa-
tients were categorized as having the following: 1)
metabolic syndrome without diabetes; 2) diabetes;
or 3) neither diabetes nor metabolic syndrome. The
main ﬁnding was that M-mode–derived LV mass
(adjusted for age, sex, ethnicity, body mass index,
fasting glucose concentration, blood pressure,
serum lipid levels, and medications) was positively
associated with cardiovascular events in those
patients with neither condition or with metabolic
syndrome, but surprisingly not in those with dia-
betes. Several points are worthy of additional
consideration.
First, methods of assessing LV mass have evolved
from electrocardiography to M-mode, 2- and 3-
dimensional echocardiography, to cardiac computed
tomography and magnetic resonance imaging (MRI).
This evolution has yielded increasingly more accurate
and reproducible methods of measuring LV mass and
volumes (1,10). The use of M-mode in the current
study could have affected the results.
Second, determining whether LV mass is appro-
priate for body size is troublesome. Guidelines
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1017recommend use of body surface area for indexing heart
size to body size (11); however, this method tends to
underestimate the degree of hypertrophy in obese
patients and give false impressions of changes in LV
mass if people gain or lose weight. Many investigators
have used height (5) or height raised to a power
between 1.7 and 2.7 to approximate lean body size from
a parameter that does not change with adiposity
(height) (12). Allometric scaling factors are intended to
relate height to ideal body size by using a power law.
Unfortunately, the human form is very complex, and
there is currently no single allometric scaling factor
that is widely accepted. The recently published Echo-
NoRMAL (Echocardiographic Normal Ranges Meta-
Analysis of the Left Heart) study (5), which attempted
to establish normative values for LV and left atrial
sizes in both the sexes and multiple ethnic groups,
used the simple and easily understandable standard
of height without allometric adjustment as themethod
of indexing.
Third, the study touches on the question of
whether diabetes directly causes or contributes to LV
hypertrophy. To this point, 1,017 type 1 diabetic
subjects from the Diabetes Control and Complications
Trial had cardiac MRI performed at a mean of 21 years
after enrollment in the trial (13). Mean LV mass and
LV mass/LV end-diastolic volume were within normal
ranges and only weakly associated with mean glyco-
sylated hemoglobin (HbA1c) concentrations over the
prior 21 years. Thus, type 1 diabetes appears, at most,
to be a rather weak contributor to the development of
LV hypertrophy. In comparison, type 2 diabetes
seems more strongly associated with LV hypertrophy,
although it is likely that obesity and other comor-
bidities mediate some or all of this association (14).
The ﬁndings of Hoang et al. (9) show a graded rela-
tionship between LV mass and cardiovascular event
rates in the diabetic group, but this was no longer
statistically signiﬁcant after multivariate adjustment.
This unexpected ﬁnding is most likely related either
to statistical chance, given that the study was not
designed to test this question, or to the overall high
risk of adverse cardiac events in diabetics, whichoverwhelmed the predictive value of LV mass in this
group.
How does measurement of LV mass help us clini-
cally? Although measuring LV mass gives prognostic
information, it does not directly guide many treat-
ment decisions, including goals for blood pressure,
body mass index, HbA1c, and low-density lipoprotein
(LDL) cholesterol. Treatment of heart failure is guided
mainly by measurement of LV ejection fraction to
differentiate between subjects in whom it is pre-
served and those in whom it is reduced. Use of
implantable cardioverter-deﬁbrillators is also driven
by LV ejection fraction, but rarely by LV mass. On the
other hand, identiﬁcation of LV hypertrophy may
help to identify causes of symptoms. Increased LV
mass is included as a diagnostic criterion for the
diagnosis of heart failure with preserved ejection
fraction (15). Measurement of LV mass is sometimes
used as a means to assess long-term blood pressure
control. Finally, documenting the presence or
absence of LV hypertrophy may be helpful in assess-
ing patients with aortic stenosis when traditional
criteria for grading the severity are ambiguous.
Given that LV mass measurements are easy to
obtain using modern imaging techniques, we should
report this parameter when such tests are ordered for
appropriate clinical indications. Absolute LV mass or
LV mass indexed to some measurement of height is
probably more meaningful than mass indexed to body
surface area because of the high prevalence of obesity
in our society. Using LV mass as a screening test does
not appear to be warranted at this point in time.
However, the dramatic advances occurring simulta-
neously in cardiac imaging, genomics, proteomics,
metabolomics, and population science bode well for
the resurgence of cardiac morphomics as a ﬁeld of
inquiry that has high potential to lead to important
new discoveries and therapeutic opportunities.
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